Table_12_Association of Soluble HLA-G Plasma Level and HLA-G Genetic Polymorphism With Pregnancy Outcome of Patients Undergoing in vitro Fertilization Embryo Transfer.DOCX
Infertility is currently a growing problem observed around the world and is estimated to affect between 8 and 12% of reproductive-aged couples worldwide. Artificial reproductive techniques are the last chance for couples seeking their own child. Human leukocyte antigen (HLA)-G expression has been suggested as an immunomodulatory molecule that influences pregnancy outcome. The HLA-G gene encodes either membrane-bound or/and soluble proteins. The aim of this study was the evaluation of the role of soluble HLA-G (sHLA-G) and its gene polymorphism in successful implantation after in vitro fertilization embryo transfers (IVF-ETs) in different clinical protocols. We tested the HLA-G polymorphism in three positions: rs1632947: c.-964G>A; rs1233334: c.-725G>C/T in promoter region; rs371194629: c.*65_*66insATTTGTTCATGCCT in 3′ untranslated region of exon 8, in 389 patients who underwent IVF-ETs and 320 women with healthy children born after natural conception. Among the patient group, 239 women were with recurrent implantation failure and 117 women had an ongoing pregnancy or a child born after IVF-ET. We found that certain rs1632947-rs1233334-rs371194629 HLA-G haplotypes and diplotypes were associated with infertility, while others were protective. The lowest secretors of sHLA-G were G-C-ins haplotype carriers (37.21 IU/ml), while the highest -G-C-del carriers (73.80 IU/ml). Other haplotype carriers were intermediate secretors. In our study, regardless of possessed haplotype by the patient, 59.73 IU/ml sHLA-G was the threshold value with the best sensitivity (58.82%) and specificity (66.10%) to discriminate patients who achieved and maintained pregnancy from those who did not conceive or they had miscarriage (p = 0.0085; likelihood ratio, 1.74; 95% CI = 0.55–0.78). However, we do not exclude that factors other than sHLA-G may also contribute to complications in pregnancy. In addition, we found that IVF patients in cycles when frozen/thawed embryo was transferred secreted higher soluble HLA-G levels than patients with fresh embryo transferred (p = 0.021). Moreover, correlation analysis of sHLA-G concentration measured before and after embryo transfer for particular patients indicated short ovarian stimulation with gonadotropin-releasing hormone antagonist as more beneficial than long protocol with gonadotropin-releasing hormone agonist. Our study confirms a role of HLA-G polymorphism in infertility and soluble HLA-G in the early stages of pregnancy.
History
References
- https://doi.org//10.1093/humupd/dmv016
- https://doi.org//10.1016/j.bbadis.2012.05.017
- https://doi.org//10.1016/j.rbmo.2017.09.012
- https://doi.org//10.1016/j.rbmo.2013.12.006
- https://doi.org//10.1016/j.rbmo.2014.03.003
- https://doi.org//10.1016/j.fertnstert.2012.03.010
- https://doi.org//10.3109/01443615.2013.782280
- https://doi.org//10.1016/j.jri.2011.05.002
- https://doi.org//10.1016/j.rbmo.2013.08.011
- https://doi.org//10.1155/2014/591489
- https://doi.org//10.3389/fimmu.2015.00128
- https://doi.org//10.3389/fimmu.2014.00198
- https://doi.org//10.1016/j.it.2017.01.009
- https://doi.org//10.1007/s00018-010-0580-7
- https://doi.org//10.1111/j.1399-0039.2009.01438.x
- https://doi.org//10.1016/j.placenta.2008.04.007
- https://doi.org//10.4049/jimmunol.1001081
- https://doi.org//10.1016/j.fertnstert.2013.07.1977
- https://doi.org//10.1111/j.1600-0897.2009.00742.x
- https://doi.org//10.1016/j.humimm.2016.01.019
- https://doi.org//10.1016/S0198-8859(00)00123-3
- https://doi.org//10.1080/08820139.2018.1467925
- https://doi.org//10.1016/j.semcancer.2007.07.004
- https://doi.org//10.1007/s00262-019-02373-1
- https://doi.org//10.3389/fimmu.2018.02164
- https://doi.org//10.1016/j.humimm.2018.05.003
- https://doi.org//10.1016/bs.ai.2015.04.001
- https://doi.org//10.1111/j.1399-0039.2004.00239.x
- https://doi.org//10.1371/journal.pone.0071742
- https://doi.org//10.1016/j.humimm.2003.08.347
- https://doi.org//10.1111/j.1399-0039.2008.01107.x
- https://doi.org//10.1016/j.humimm.2005.12.003
- https://doi.org//10.1007/s10815-013-0155-2
- https://doi.org//10.1016/j.humimm.2015.02.004
- https://doi.org//10.1111/tan.12056
- https://doi.org//10.1016/j.humimm.2011.02.011
- https://doi.org//10.1016/j.fertnstert.2019.05.003
- https://doi.org//10.3389/fimmu.2014.00476
- https://doi.org//10.1155/2014/734068
- https://doi.org//10.1093/hmg/ddi389
- https://doi.org//10.1086/375501
- https://doi.org//10.1093/humrep/del036
- https://doi.org//10.1111/j.1744-313X.2010.00926.x
- https://doi.org//10.1111/tan.12561
- https://doi.org//10.1007/s00005-016-0389-7
- https://doi.org//10.1007/s00438-017-1404-3
- https://doi.org//10.1016/j.rbmo.2019.05.023
- https://doi.org//10.1097/OGX.0000000000000043
- https://doi.org//10.1016/j.rbmo.2012.02.021
- https://doi.org//10.1007/s10815-017-0994-3
- https://doi.org//10.1111/tan.12452
- https://doi.org//10.3390/ijerph16060982
- https://doi.org//10.1016/j.humimm.2012.11.016
- https://doi.org//10.1034/j.1399-0039.2001.057001015.x
- https://doi.org//10.1016/j.humimm.2016.09.002
- https://doi.org//10.1111/jog.13377
- https://doi.org//10.1186/s12958-016-0225-2
- https://doi.org//10.1093/humupd/dmx031
- https://doi.org//10.1093/humrep/dei305
- https://doi.org//10.1515/hmbci-2016-0038
- https://doi.org//10.1080/09513590.2017.1291615
- https://doi.org//10.1016/j.fertnstert.2014.12.128
- https://doi.org//10.1530/EJE-19-0379
- https://doi.org//10.1093/humrep/dew358
- https://doi.org//10.1016/j.rbmo.2019.05.010
- https://doi.org//10.1073/pnas.1602886113
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity